Table 3.
Univariate analysis of factors associated with clinical response and remission with the second anti-TNF in the whole cohort (N = 473).
| Variable | Response at week 14 | p | Remission at week 52 | p | ||
|---|---|---|---|---|---|---|
| No | Yes | No | Yes | |||
| Female gender | 46% | 49% | 0.518 | 47.9% | 45.9% | 0.764 |
| Never smoker | 65.7% | 63% | 0.752 | 65.7% | 62.1% | 0.719 |
| Extensive colitis | 58.6% | 59.5% | 0.851 | 59.9% | 57.4% | 1 |
| Age at first anti-TNF, median (range interval) | 42 (20) | 42 (22) | 0.815 | 42 (20) | 44 (21) | 0.438 |
| Disease duration at the beginning of the first anti-TNF, median (range interval) | 43 (89) | 49.5 (91) | 0.661 | 45 (87) | 47 (106) | 0.872 |
| Concomitant immunosuppressant with first anti-TNF | 58.6% | 49.5% | 0.052 | 54.7% | 50.7% | 0.425 |
| Dose escalation of first anti-TNF | 46% | 38.6% | 0.112 | 47.9% | 32.4% | <0.001 |
| Cause for discontinuation of first anti-TNF | <0.001 | <0.001 | ||||
| Secondary loss of response | 34.6% | 38.1% | 37.5% | 33.1% | ||
| Primary partial/nonresponse | 41.8% | 25.7% | 39.2% | 25.7% | ||
| Adverse effect | 20.2% | 27.1% | 19.1% | 31.1% | ||
| Time on the first anti-TNF, median (range interval) | 28.1 (45.9) | 40.1 (75.6) | 0.038 | 30.7 (55) | 36.3 (76) | 0.649 |
| Disease duration at the beginning of the second anti-TNF, median (range interval) | 60 (98) | 76.5 (108) | 0.491 | 62 (100) | 78 (116) | 0.463 |
| Concomitant immunosuppressant with second anti-TNF | 54.4% | 49.5% | 0.309 | 51.8% | 50.7% | 0.842 |
| Moderate-to-severe partial Mayo score at the beginning of the second anti-TNF | 66% | 63.3% | 0.622 | 69.8% | 54.3% | <0.001 |
| Moderate-to-severe Mayo endoscopic subscore at the beginning of the second anti-TNF | 89.7% | 84.4% | 0.226 | 87.6% | 85.7% | 0.709 |
Bold and italic characters within the Tables are used to highlight statistically significant results.